When was sofosbuvir approved?
When was sofosbuvir approved?
Development Timeline for Sovaldi
| Date | Article |
|---|---|
| Apr 7, 2017 | Approval FDA Approves Sovaldi (sofosbuvir) for Chronic Hepatitis C Infection in Pediatric Patients 12 Years and Older |
| Dec 6, 2013 | Approval FDA Approves Sovaldi for Chronic Hepatitis C |
Is sofosbuvir FDA approved?
U.S. Food and Drug Administration Approves Gilead’s Sovaldi™ (Sofosbuvir) for the Treatment of Chronic Hepatitis C. Sovaldi in combination with ribavirin for 24 weeks can be considered for CHC patients with genotype 1 infection who are interferon ineligible.
Why was daclatasvir discontinued?
FDA denies approval due to discontinuation of asunaprevir development. Bristol-Myers Squibb (BMS) has been blocked from getting US approval for hepatitis C virus (HCV) drug daclatasvir because the drug it was developed alongside has been dropped from development.
What class of drug is daclatasvir?
Daclatasvir is in a class of antiviral medications called hepatitis C virus (HCV) NS5A inhibitors. It works by stopping the virus that causes hepatitis C from spreading inside the body. It is not known if daclatasvir prevents the spread of hepatitis C to other people.
Who makes Sofosbuvir?
History. Sofosbuvir was discovered in 2007 by Michael Sofia, a scientist at Pharmasset, and the drug was first tested in people in 2010. In 2011, Gilead Sciences bought Pharmasset for about $11 billion.
What are common side effects of Daclatasvir?
Common side effects of Daklinza include:
- headache,
- fatigue,
- nausea,
- diarrhea,
- low levels of iron in the blood (anemia),
- rash,
- insomnia,
- dizziness, and.
Who makes Vosevi?
The FDA granted approval of Vosevi to Gilead Sciences Inc.
How much does daclatasvir cost?
A 12-week course of daclatasvir is priced at US$63,000 in the US [3].
